Passage Bio, Inc.
A clinical-stage gene therapy company developing one-time treatments for rare brain and nervous-system diseases. Founded in 2019 as a spinout of the University of Pennsylvania's Gene Therapy Program, it builds on the work of gene-therapy pioneer James Wilson. Its name comes from "passaging" — the lab process of growing and purifying the harmless viruses that carry therapeutic genes into cells. Its lead programs target rare disorders such as GM1 gangliosidosis and Krabbe disease.
1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 5.01 Changes in Control of Registrant · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.02 Termination of a Material Definitive Agreement
5.07 Submission of Matters to a Vote of Security Holders
2.05 Costs Associated with Exit or Disposal Activities
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
1.02 Termination of a Material Definitive Agreement
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits